Product Description
A highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. TPM-1116 represents a new chemical series of OX2R agonists with the potential for a best-in-class clinical profile. (Sourced from: https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-announces-exclusive-agreement-develop-and)
Mechanisms of Action: OX2R Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Harmony Biosciences, LLC
Company Location: PLYMOUTH MEETING PA 19462
Company CEO: John C. Jacobs
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for TPM-1116](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Narcolepsy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|